Share Price and Basic Stock Data
Last Updated: February 6, 2026, 8:54 pm
| PEG Ratio | 0.21 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Ind-Swift Laboratories Ltd operates within the pharmaceutical sector, reporting a market capitalization of ₹898 Cr and a share price of ₹109. The company recorded sales of ₹1,207 Cr for the fiscal year ending March 2023, reflecting a steady increase from ₹1,039 Cr in the previous year. However, the latest quarterly sales figures show a decline, with ₹289.71 Cr reported in September 2023, down from ₹310.34 Cr in June 2023. This fluctuation highlights potential challenges in maintaining consistent revenue streams. The company’s revenue from operations per share stood at ₹81.71 for the fiscal year 2025, significantly lower than ₹216.78 in the previous year, indicating a downward trend. Investor interest is evident, with 43,780 shareholders currently holding stakes in the company. The historical sales data, alongside current performance, indicates that while there are periods of robust growth, the company faces volatility that could impact its market position.
Profitability and Efficiency Metrics
Ind-Swift Laboratories reported a net profit of ₹234 Cr for the trailing twelve months, which translates to an earnings per share (EPS) of ₹37.25 for the fiscal year 2025. This is a notable improvement from the previous fiscal year’s EPS of ₹71.24, though the recent quarterly EPS figures indicate a decline, with ₹0.98 recorded for September 2025. Operating profit margins (OPM) exhibited volatility, standing at 0.96% currently, compared to 19% in March 2023, reflecting operational challenges. The interest coverage ratio stood at a strong 21.24x, indicating robust capacity to meet interest obligations. However, the return on equity (ROE) was reported at 18%, which, while positive, suggests that the company may be underperforming compared to higher benchmarks typically seen in the pharmaceutical sector. The cash conversion cycle at 112 days reveals inefficiencies in converting sales into cash, necessitating improvements in operational management.
Balance Sheet Strength and Financial Ratios
On the balance sheet front, Ind-Swift Laboratories reported total reserves of ₹1,226 Cr and borrowings of ₹22 Cr, indicating a low leverage ratio and a conservative capital structure. The total liabilities stood at ₹1,438 Cr, down from ₹1,824 Cr in the previous year, showcasing a significant reduction in debt, which is favorable for financial stability. The price-to-book value ratio (P/BV) is notably low at 0.49x, suggesting that the stock may be undervalued compared to its book value. The current ratio of 3.92x indicates strong liquidity, allowing the company to cover short-term obligations comfortably. However, the return on capital employed (ROCE) at 3.08% is low, signaling potential inefficiencies in utilizing capital for generating profits. Overall, while the balance sheet shows strength in terms of low debt and high liquidity, the profitability ratios indicate areas that require strategic focus and improvement.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Ind-Swift Laboratories reveals a diverse ownership structure, with promoters holding 39.49% of the equity. Foreign institutional investors (FIIs) have increased their stake significantly to 14.80%, indicating growing confidence from international investors. Domestic institutional investors (DIIs) hold a mere 0.68%, while public shareholders account for 45.02%. The increase in FIIs from 0.04% in December 2022 to the current level demonstrates a positive shift in investor sentiment. The number of shareholders has also risen to 43,780, reflecting increased retail investor participation. However, the declining promoter stake from 42.01% in March 2023 to the current level may raise concerns about long-term commitment. The shifting dynamics of shareholding suggest a mixed outlook on investor confidence, with strong FII interest potentially offsetting the declining promoter stake.
Outlook, Risks, and Final Insight
The outlook for Ind-Swift Laboratories hinges on its ability to stabilize revenue and enhance profitability amidst operational challenges. The company’s strong interest coverage ratio and low debt levels provide a buffer against financial distress. However, risks include the declining sales trend and fluctuating profit margins, which could impact future growth prospects. Additionally, the low ROCE suggests inefficiencies that need addressing to optimize capital use. The increasing FII stake is a positive signal, yet the declining promoter share could imply concerns about long-term management commitment. Moving forward, the company must focus on streamlining operations, enhancing cash flow management, and potentially exploring strategic partnerships to leverage its financial strengths while mitigating risks associated with market volatility and operational inefficiencies.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 128 Cr. | 102 | 188/84.3 | 28.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,527 Cr. | 324 | 479/192 | 73.8 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.8 Cr. | 44.2 | 82.0/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 79.0 Cr. | 53.9 | 54.0/17.0 | 188 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,603.26 Cr | 1,093.01 | 42.95 | 202.24 | 0.37% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 312.69 | 304.25 | 310.34 | 289.71 | 287.51 | 528.57 | 33.17 | 11.96 | 128.80 | 138.24 | 152.73 | 152.64 | 150.85 |
| Expenses | 258.93 | 240.58 | 250.05 | 224.02 | 235.82 | 437.36 | 42.91 | 23.76 | 135.45 | 147.44 | 149.13 | 151.17 | 146.68 |
| Operating Profit | 53.76 | 63.67 | 60.29 | 65.69 | 51.69 | 91.21 | -9.74 | -11.80 | -6.65 | -9.20 | 3.60 | 1.47 | 4.17 |
| OPM % | 17.19% | 20.93% | 19.43% | 22.67% | 17.98% | 17.26% | -29.36% | -98.66% | -5.16% | -6.66% | 2.36% | 0.96% | 2.76% |
| Other Income | 8.36 | -16.44 | 5.61 | 7.40 | 7.11 | 458.23 | 11.14 | 13.01 | 15.91 | 220.34 | 14.58 | 17.86 | 21.73 |
| Interest | 22.38 | 21.82 | 20.38 | 21.14 | 21.05 | 2.96 | 0.17 | 0.41 | 10.03 | -26.76 | 1.15 | 2.01 | 0.67 |
| Depreciation | 15.39 | 9.29 | 13.89 | 13.19 | 13.56 | 19.55 | 0.25 | 0.22 | 5.81 | 7.44 | 6.68 | 6.98 | 8.84 |
| Profit before tax | 24.35 | 16.12 | 31.63 | 38.76 | 24.19 | 526.93 | 0.98 | 0.58 | -6.58 | 230.46 | 10.35 | 10.34 | 16.39 |
| Tax % | -13.43% | 255.40% | 45.02% | 17.88% | 19.31% | 6.29% | -3.06% | 31.03% | -16.41% | 3.55% | 16.52% | 22.24% | 41.92% |
| Net Profit | 27.50 | -25.12 | 17.24 | 31.66 | 19.42 | 493.68 | 0.94 | 0.41 | -5.49 | 222.27 | 8.77 | 7.99 | 9.54 |
| EPS in Rs | 4.65 | -4.25 | 2.92 | 5.36 | 3.29 | 83.55 | 0.16 | 0.07 | -0.93 | 36.67 | 1.45 | 0.98 | 1.17 |
Last Updated: February 5, 2026, 1:08 pm
Below is a detailed analysis of the quarterly data for Ind-Swift Laboratories Ltd based on the most recent figures (Dec 2025) and their trends compared to the previous period:
- For Sales, as of Dec 2025, the value is 150.85 Cr.. The value appears to be declining and may need further review. It has decreased from 152.64 Cr. (Sep 2025) to 150.85 Cr., marking a decrease of 1.79 Cr..
- For Expenses, as of Dec 2025, the value is 146.68 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 151.17 Cr. (Sep 2025) to 146.68 Cr., marking a decrease of 4.49 Cr..
- For Operating Profit, as of Dec 2025, the value is 4.17 Cr.. The value appears strong and on an upward trend. It has increased from 1.47 Cr. (Sep 2025) to 4.17 Cr., marking an increase of 2.70 Cr..
- For OPM %, as of Dec 2025, the value is 2.76%. The value appears strong and on an upward trend. It has increased from 0.96% (Sep 2025) to 2.76%, marking an increase of 1.80%.
- For Other Income, as of Dec 2025, the value is 21.73 Cr.. The value appears strong and on an upward trend. It has increased from 17.86 Cr. (Sep 2025) to 21.73 Cr., marking an increase of 3.87 Cr..
- For Interest, as of Dec 2025, the value is 0.67 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2.01 Cr. (Sep 2025) to 0.67 Cr., marking a decrease of 1.34 Cr..
- For Depreciation, as of Dec 2025, the value is 8.84 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6.98 Cr. (Sep 2025) to 8.84 Cr., marking an increase of 1.86 Cr..
- For Profit before tax, as of Dec 2025, the value is 16.39 Cr.. The value appears strong and on an upward trend. It has increased from 10.34 Cr. (Sep 2025) to 16.39 Cr., marking an increase of 6.05 Cr..
- For Tax %, as of Dec 2025, the value is 41.92%. The value appears to be increasing, which may not be favorable. It has increased from 22.24% (Sep 2025) to 41.92%, marking an increase of 19.68%.
- For Net Profit, as of Dec 2025, the value is 9.54 Cr.. The value appears strong and on an upward trend. It has increased from 7.99 Cr. (Sep 2025) to 9.54 Cr., marking an increase of 1.55 Cr..
- For EPS in Rs, as of Dec 2025, the value is 1.17. The value appears strong and on an upward trend. It has increased from 0.98 (Sep 2025) to 1.17, marking an increase of 0.19.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:11 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 965 | 660 | 653 | 716 | 765 | 757 | 780 | 891 | 1,039 | 1,207 | 1,709 | 562 | 568 |
| Expenses | 906 | 571 | 546 | 610 | 631 | 630 | 635 | 709 | 837 | 978 | 1,403 | 581 | 579 |
| Operating Profit | 59 | 89 | 107 | 106 | 134 | 126 | 144 | 183 | 202 | 229 | 306 | -19 | -11 |
| OPM % | 6% | 13% | 16% | 15% | 18% | 17% | 19% | 21% | 19% | 19% | 18% | -3% | -2% |
| Other Income | -19 | -31 | 1 | 15 | 16 | 120 | 33 | 23 | 37 | 7 | 476 | 305 | 269 |
| Interest | 117 | 117 | 106 | 88 | 28 | 92 | 107 | 100 | 96 | 92 | 104 | 3 | -14 |
| Depreciation | 66 | 84 | 85 | 88 | 87 | 104 | 90 | 87 | 131 | 57 | 80 | 24 | 27 |
| Profit before tax | -142 | -143 | -83 | -55 | 36 | 50 | -20 | 18 | 13 | 87 | 598 | 258 | 245 |
| Tax % | -14% | -17% | -29% | -29% | 39% | 42% | 7% | 117% | 117% | 45% | 10% | 3% | |
| Net Profit | -122 | -119 | -59 | -39 | 22 | 29 | -21 | -3 | -2 | 48 | 539 | 250 | 234 |
| EPS in Rs | -29.79 | -29.14 | -14.33 | -8.75 | 4.85 | 6.09 | -3.59 | -0.53 | -0.36 | 8.06 | 91.18 | 41.32 | 38.17 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 2.46% | 50.42% | 33.90% | 156.41% | 31.82% | -172.41% | 85.71% | 33.33% | 2500.00% | 1022.92% | -53.62% |
| Change in YoY Net Profit Growth (%) | 0.00% | 47.96% | -16.52% | 122.51% | -124.59% | -204.23% | 258.13% | -52.38% | 2466.67% | -1477.08% | -1076.53% |
Ind-Swift Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | -6% |
| 3 Years: | -19% |
| TTM: | -62% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 30% |
| 3 Years: | 205% |
| TTM: | -88% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 24% |
| 3 Years: | 20% |
| 1 Year: | -32% |
| Return on Equity | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 6% |
| 3 Years: | 10% |
| Last Year: | 4% |
Last Updated: September 5, 2025, 7:30 am
Balance Sheet
Last Updated: December 10, 2025, 2:51 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 41 | 42 | 42 | 45 | 46 | 48 | 60 | 60 | 60 | 60 | 67 | 69 | 82 |
| Reserves | 684 | 553 | 476 | 486 | 507 | 540 | 581 | 544 | 541 | 622 | 745 | 1,104 | 1,226 |
| Borrowings | 1,355 | 1,413 | 1,457 | 1,242 | 1,083 | 1,148 | 1,031 | 1,005 | 953 | 862 | 217 | 41 | 22 |
| Other Liabilities | 258 | 236 | 240 | 364 | 387 | 188 | 198 | 210 | 247 | 280 | 432 | 224 | 215 |
| Total Liabilities | 2,339 | 2,244 | 2,215 | 2,138 | 2,023 | 1,924 | 1,870 | 1,818 | 1,801 | 1,824 | 1,460 | 1,438 | 1,544 |
| Fixed Assets | 1,174 | 1,117 | 1,099 | 1,042 | 934 | 914 | 843 | 753 | 630 | 587 | 192 | 273 | 285 |
| CWIP | 78 | 113 | 78 | 70 | 69 | 20 | 11 | 19 | 10 | 8 | 51 | 0 | 0 |
| Investments | 17 | 18 | 18 | 18 | 18 | 19 | 17 | 36 | 29 | 30 | 112 | 213 | 312 |
| Other Assets | 1,070 | 997 | 1,020 | 1,007 | 1,002 | 972 | 998 | 1,011 | 1,131 | 1,199 | 1,106 | 952 | 947 |
| Total Assets | 2,339 | 2,244 | 2,215 | 2,138 | 2,023 | 1,924 | 1,870 | 1,818 | 1,801 | 1,824 | 1,460 | 1,438 | 1,544 |
Below is a detailed analysis of the balance sheet data for Ind-Swift Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 82.00 Cr.. The value appears strong and on an upward trend. It has increased from 69.00 Cr. (Mar 2025) to 82.00 Cr., marking an increase of 13.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,226.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,104.00 Cr. (Mar 2025) to 1,226.00 Cr., marking an increase of 122.00 Cr..
- For Borrowings, as of Sep 2025, the value is 22.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 41.00 Cr. (Mar 2025) to 22.00 Cr., marking a decrease of 19.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 215.00 Cr.. The value appears to be improving (decreasing). It has decreased from 224.00 Cr. (Mar 2025) to 215.00 Cr., marking a decrease of 9.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,544.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,438.00 Cr. (Mar 2025) to 1,544.00 Cr., marking an increase of 106.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 285.00 Cr.. The value appears strong and on an upward trend. It has increased from 273.00 Cr. (Mar 2025) to 285.00 Cr., marking an increase of 12.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 312.00 Cr.. The value appears strong and on an upward trend. It has increased from 213.00 Cr. (Mar 2025) to 312.00 Cr., marking an increase of 99.00 Cr..
- For Other Assets, as of Sep 2025, the value is 947.00 Cr.. The value appears to be declining and may need further review. It has decreased from 952.00 Cr. (Mar 2025) to 947.00 Cr., marking a decrease of 5.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,544.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,438.00 Cr. (Mar 2025) to 1,544.00 Cr., marking an increase of 106.00 Cr..
Notably, the Reserves (1,226.00 Cr.) exceed the Borrowings (22.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 58.00 | 88.00 | 106.00 | 105.00 | 133.00 | 125.00 | 143.00 | 182.00 | -751.00 | -633.00 | 89.00 | -60.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 168 | 215 | 208 | 182 | 194 | 169 | 186 | 177 | 160 | 153 | 48 | 107 |
| Inventory Days | 182 | 312 | 368 | 305 | 291 | 284 | 315 | 301 | 288 | 242 | 6 | 145 |
| Days Payable | 103 | 120 | 137 | 91 | 118 | 114 | 124 | 111 | 118 | 113 | 52 | 140 |
| Cash Conversion Cycle | 247 | 407 | 439 | 396 | 367 | 339 | 377 | 367 | 330 | 282 | 2 | 112 |
| Working Capital Days | 129 | 141 | -26 | -97 | -49 | 217 | 248 | 253 | 253 | 234 | 2 | 141 |
| ROCE % | 0% | 1% | 2% | 2% | 4% | 4% | 5% | 7% | 7% | 13% | 20% | 3% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 37.25 | 71.24 | 8.10 | -0.36 | -0.53 |
| Diluted EPS (Rs.) | 35.21 | 71.24 | 8.10 | -0.36 | -0.53 |
| Cash EPS (Rs.) | 40.00 | 80.35 | 17.59 | 21.55 | 14.07 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 170.88 | 157.64 | 83.36 | 67.61 | 65.66 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 170.88 | 157.64 | 114.02 | 100.47 | 100.90 |
| Revenue From Operations / Share (Rs.) | 81.71 | 216.78 | 201.87 | 173.68 | 149.04 |
| PBDIT / Share (Rs.) | 9.02 | 50.70 | 43.92 | 39.98 | 34.36 |
| PBIT / Share (Rs.) | 5.46 | 41.68 | 34.33 | 18.07 | 19.77 |
| PBT / Share (Rs.) | 37.50 | 98.46 | 14.47 | 2.10 | 3.01 |
| Net Profit / Share (Rs.) | 36.44 | 71.33 | 8.00 | -0.35 | -0.52 |
| NP After MI And SOA / Share (Rs.) | 36.44 | 71.24 | 7.96 | -0.35 | -0.52 |
| PBDIT Margin (%) | 11.03 | 23.38 | 21.75 | 23.01 | 23.05 |
| PBIT Margin (%) | 6.67 | 19.22 | 17.00 | 10.40 | 13.26 |
| PBT Margin (%) | 45.89 | 45.41 | 7.16 | 1.20 | 2.02 |
| Net Profit Margin (%) | 44.60 | 32.90 | 3.96 | -0.20 | -0.35 |
| NP After MI And SOA Margin (%) | 44.59 | 32.86 | 3.94 | -0.20 | -0.35 |
| Return on Networth / Equity (%) | 21.32 | 45.19 | 9.54 | -0.53 | -0.80 |
| Return on Capital Employeed (%) | 3.08 | 26.09 | 14.13 | 7.36 | 7.86 |
| Return On Assets (%) | 17.41 | 36.13 | 2.60 | -0.11 | -0.17 |
| Long Term Debt / Equity (X) | 0.01 | 0.01 | 1.51 | 2.10 | 2.25 |
| Total Debt / Equity (X) | 0.02 | 0.01 | 1.73 | 2.35 | 2.56 |
| Asset Turnover Ratio (%) | 0.43 | 0.85 | 0.66 | 0.54 | 0.46 |
| Current Ratio (X) | 3.92 | 2.99 | 3.14 | 3.22 | 3.00 |
| Quick Ratio (X) | 3.41 | 2.94 | 1.96 | 1.94 | 1.81 |
| Inventory Turnover Ratio (X) | 9.01 | 5.70 | 1.52 | 1.33 | 1.23 |
| Interest Coverage Ratio (X) | 21.24 | 5.86 | 2.85 | 2.50 | 2.05 |
| Interest Coverage Ratio (Post Tax) (X) | 10.36 | 1.68 | 1.81 | 0.97 | 0.96 |
| Enterprise Value (Cr.) | 189.85 | 165.50 | 1173.71 | 1328.01 | 1424.06 |
| EV / Net Operating Revenue (X) | 0.33 | 0.12 | 0.97 | 1.28 | 1.60 |
| EV / EBITDA (X) | 3.06 | 0.55 | 4.47 | 5.55 | 6.93 |
| MarketCap / Net Operating Revenue (X) | 1.03 | 0.45 | 0.27 | 0.38 | 0.48 |
| Price / BV (X) | 0.49 | 0.62 | 0.66 | 0.98 | 1.10 |
| Price / Net Operating Revenue (X) | 1.03 | 0.45 | 0.27 | 0.38 | 0.48 |
| EarningsYield | 0.43 | 0.72 | 0.14 | -0.01 | -0.01 |
After reviewing the key financial ratios for Ind-Swift Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 37.25. This value is within the healthy range. It has decreased from 71.24 (Mar 24) to 37.25, marking a decrease of 33.99.
- For Diluted EPS (Rs.), as of Mar 25, the value is 35.21. This value is within the healthy range. It has decreased from 71.24 (Mar 24) to 35.21, marking a decrease of 36.03.
- For Cash EPS (Rs.), as of Mar 25, the value is 40.00. This value is within the healthy range. It has decreased from 80.35 (Mar 24) to 40.00, marking a decrease of 40.35.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 170.88. It has increased from 157.64 (Mar 24) to 170.88, marking an increase of 13.24.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 170.88. It has increased from 157.64 (Mar 24) to 170.88, marking an increase of 13.24.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 81.71. It has decreased from 216.78 (Mar 24) to 81.71, marking a decrease of 135.07.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 9.02. This value is within the healthy range. It has decreased from 50.70 (Mar 24) to 9.02, marking a decrease of 41.68.
- For PBIT / Share (Rs.), as of Mar 25, the value is 5.46. This value is within the healthy range. It has decreased from 41.68 (Mar 24) to 5.46, marking a decrease of 36.22.
- For PBT / Share (Rs.), as of Mar 25, the value is 37.50. This value is within the healthy range. It has decreased from 98.46 (Mar 24) to 37.50, marking a decrease of 60.96.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 36.44. This value is within the healthy range. It has decreased from 71.33 (Mar 24) to 36.44, marking a decrease of 34.89.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 36.44. This value is within the healthy range. It has decreased from 71.24 (Mar 24) to 36.44, marking a decrease of 34.80.
- For PBDIT Margin (%), as of Mar 25, the value is 11.03. This value is within the healthy range. It has decreased from 23.38 (Mar 24) to 11.03, marking a decrease of 12.35.
- For PBIT Margin (%), as of Mar 25, the value is 6.67. This value is below the healthy minimum of 10. It has decreased from 19.22 (Mar 24) to 6.67, marking a decrease of 12.55.
- For PBT Margin (%), as of Mar 25, the value is 45.89. This value is within the healthy range. It has increased from 45.41 (Mar 24) to 45.89, marking an increase of 0.48.
- For Net Profit Margin (%), as of Mar 25, the value is 44.60. This value exceeds the healthy maximum of 10. It has increased from 32.90 (Mar 24) to 44.60, marking an increase of 11.70.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 44.59. This value exceeds the healthy maximum of 20. It has increased from 32.86 (Mar 24) to 44.59, marking an increase of 11.73.
- For Return on Networth / Equity (%), as of Mar 25, the value is 21.32. This value is within the healthy range. It has decreased from 45.19 (Mar 24) to 21.32, marking a decrease of 23.87.
- For Return on Capital Employeed (%), as of Mar 25, the value is 3.08. This value is below the healthy minimum of 10. It has decreased from 26.09 (Mar 24) to 3.08, marking a decrease of 23.01.
- For Return On Assets (%), as of Mar 25, the value is 17.41. This value is within the healthy range. It has decreased from 36.13 (Mar 24) to 17.41, marking a decrease of 18.72.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.02. This value is within the healthy range. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.43. It has decreased from 0.85 (Mar 24) to 0.43, marking a decrease of 0.42.
- For Current Ratio (X), as of Mar 25, the value is 3.92. This value exceeds the healthy maximum of 3. It has increased from 2.99 (Mar 24) to 3.92, marking an increase of 0.93.
- For Quick Ratio (X), as of Mar 25, the value is 3.41. This value exceeds the healthy maximum of 2. It has increased from 2.94 (Mar 24) to 3.41, marking an increase of 0.47.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 9.01. This value exceeds the healthy maximum of 8. It has increased from 5.70 (Mar 24) to 9.01, marking an increase of 3.31.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 21.24. This value is within the healthy range. It has increased from 5.86 (Mar 24) to 21.24, marking an increase of 15.38.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 10.36. This value is within the healthy range. It has increased from 1.68 (Mar 24) to 10.36, marking an increase of 8.68.
- For Enterprise Value (Cr.), as of Mar 25, the value is 189.85. It has increased from 165.50 (Mar 24) to 189.85, marking an increase of 24.35.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.33. This value is below the healthy minimum of 1. It has increased from 0.12 (Mar 24) to 0.33, marking an increase of 0.21.
- For EV / EBITDA (X), as of Mar 25, the value is 3.06. This value is below the healthy minimum of 5. It has increased from 0.55 (Mar 24) to 3.06, marking an increase of 2.51.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.03. This value is within the healthy range. It has increased from 0.45 (Mar 24) to 1.03, marking an increase of 0.58.
- For Price / BV (X), as of Mar 25, the value is 0.49. This value is below the healthy minimum of 1. It has decreased from 0.62 (Mar 24) to 0.49, marking a decrease of 0.13.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.03. This value is within the healthy range. It has increased from 0.45 (Mar 24) to 1.03, marking an increase of 0.58.
- For EarningsYield, as of Mar 25, the value is 0.43. This value is below the healthy minimum of 5. It has decreased from 0.72 (Mar 24) to 0.43, marking a decrease of 0.29.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Ind-Swift Laboratories Ltd:
- Net Profit Margin: 44.6%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 3.08% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 21.32% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 10.36
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.41
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 22.7 (Industry average Stock P/E: 42.95)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.02
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 44.6%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | SCO 850, Shivalik Enclave, Chandigarh Chandigarh 160101 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Navrattan Munjal | Chairman & Managing Director |
| Mr. Himanshu Jain | Joint Managing Director |
| Mr. Rishav Mehta | Executive Director |
| Mr. Sahil Munjal | Executive Director |
| Mr. Rajinder Kumar Gupta | Independent Director |
| Mr. Prabhat Khurana | Independent Director |
| Mr. Subodh Gupta | Independent Director |
| Ms. Neerja Chathley | Independent Woman Director |
FAQ
What is the intrinsic value of Ind-Swift Laboratories Ltd?
Ind-Swift Laboratories Ltd's intrinsic value (as of 07 February 2026) is ₹11.12 which is 91.58% lower the current market price of ₹132.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹1,077 Cr. market cap, FY2025-2026 high/low of ₹139/67.2, reserves of ₹1,226 Cr, and liabilities of ₹1,544 Cr.
What is the Market Cap of Ind-Swift Laboratories Ltd?
The Market Cap of Ind-Swift Laboratories Ltd is 1,077 Cr..
What is the current Stock Price of Ind-Swift Laboratories Ltd as on 07 February 2026?
The current stock price of Ind-Swift Laboratories Ltd as on 07 February 2026 is ₹132.
What is the High / Low of Ind-Swift Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Ind-Swift Laboratories Ltd stocks is ₹139/67.2.
What is the Stock P/E of Ind-Swift Laboratories Ltd?
The Stock P/E of Ind-Swift Laboratories Ltd is 22.7.
What is the Book Value of Ind-Swift Laboratories Ltd?
The Book Value of Ind-Swift Laboratories Ltd is 160.
What is the Dividend Yield of Ind-Swift Laboratories Ltd?
The Dividend Yield of Ind-Swift Laboratories Ltd is 0.00 %.
What is the ROCE of Ind-Swift Laboratories Ltd?
The ROCE of Ind-Swift Laboratories Ltd is 0.78 %.
What is the ROE of Ind-Swift Laboratories Ltd?
The ROE of Ind-Swift Laboratories Ltd is 0.18 %.
What is the Face Value of Ind-Swift Laboratories Ltd?
The Face Value of Ind-Swift Laboratories Ltd is 10.0.